Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 19 June 1992:
Vol. 256. no. 5064, pp. 1687 - 1690
DOI: 10.1126/science.256.5064.1687
Prev | Table of Contents | Next

Articles

Vaccine Protection of Chimpanzees Against Challenge with HIV-1-Infected Peripheral Blood Mononuclear Cells

Patricia N. Fultz , Peter Nara , Francoise Barre-Sinoussi , Agnes Chaput , Michael L. Greenberg , Elizabeth Muchmore , Marie-Paule Kieny , and Marc Girard

Because human immunodeficiency virus (HIV) can be transmitted as cell-free virus or as infected cells (cell-associated virus), vaccines must protect against infection by both viral forms. Vaccine-mediated protection of nonhuman primates against low doses of cell-free HIV-1, HIV-2, or simian immunodeficiency virus (SIV) has been demonstrated. It is now shown that multiple immunizations of chimpanzees with HIV-1 antigens protected against infection with cell-associated virus. Protection can persist for extended periods (one animal had not been exposed to viral antigens for 1 year before challenge). These results show that it is possible to elicit long-lasting protective immunity against cell-associated HIV-1.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Human Immunodeficiency Virus Type 1 Vpr Links Proteasomal Degradation and Checkpoint Activation.
J. L. DeHart and V. Planelles (2008)
J. Virol. 82, 1066-1072
   Full Text »    PDF »
Vaccine Protection against a Heterologous, Non-Syncytium-Inducing, Primary Human Immunodeficiency Virus.
M. Robert-Guroff, H. Kaur, L. J. Patterson, M. Leno, A. J. Conley, P. M. McKenna, P. D. Markham, E. Richardson, K. Aldrich, K. Arora, et al. (1998)
J. Virol. 72, 10275-10280
   Abstract »    Full Text »    PDF »
Extensive Diversification of Human Immunodeficiency Virus Type 1 Subtype B Strains during Dual Infection of a Chimpanzee That Progressed to AIDS.
Q. Wei and P. N. Fultz (1998)
J. Virol. 72, 3005-3017
   Abstract »    Full Text »    PDF »
Induction of Neutralizing Antibodies to T-Cell Line-Adapted and Primary Human Immunodeficiency Virus Type 1 Isolates with a Prime-Boost Vaccine Regimen in Chimpanzees.
S. Zolla-Pazner, M. Lubeck, S. Xu, S. Burda, R. J. Natuk, F. Sinangil, K. Steimer, R. C. Gallo, J. W. Eichberg, T. Matthews, et al. (1998)
J. Virol. 72, 1052-1059
   Abstract »    Full Text »    PDF »
Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines.
R. I. Connor, B. T. M. Korber, B. S. Graham, B. H. Hahn, D. D. Ho, B. D. Walker, A. U. Neumann, S. H. Vermund, J. Mestecky, S. Jackson, et al. (1998)
J. Virol. 72, 1552-1576
   Abstract »    Full Text »    PDF »
Candidate AIDS Vaccines.
B. S. Graham and P. F. Wright (1995)
N. Engl. J. Med. 333, 1331-1339
   Full Text »    PDF »
Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1.
R. B. Belshe, B. S. Graham, M. C. Keefer, G. J. Gorse, MD, P. Wright, R. Dolin, T. Matthews, K. Weinhold, D. P. Bolognesi, R. Sposto, et al. (1994)
JAMA 272, 475-480
   Abstract »    PDF »
VACCINE PROTECTS CHIMPS FROM HIV-INFECTED CELLS.
(1992)
Journal Watch (General) 1992, 6
   Full Text »
Chimps Protected From Infected Cells.
J. Palca (1992)
Science 256, 1632
   PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)